These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38936955)

  • 21. Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
    Fleming-Dutra KE; Jones JM; Roper LE; Prill MM; Ortega-Sanchez IR; Moulia DL; Wallace M; Godfrey M; Broder KR; Tepper NK; Brooks O; Sánchez PJ; Kotton CN; Mahon BE; Long SS; McMorrow ML
    MMWR Morb Mortal Wkly Rep; 2023 Oct; 72(41):1115-1122. PubMed ID: 37824423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Priorities for developing respiratory syncytial virus vaccines in different target populations.
    Drysdale SB; Barr RS; Rollier CS; Green CA; Pollard AJ; Sande CJ
    Sci Transl Med; 2020 Mar; 12(535):. PubMed ID: 32188721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Respiratory syncytial virus vaccines: an update on those in the immediate pipeline.
    Esposito S; Di Pietro G
    Future Microbiol; 2016 Oct; 11():1479-1490. PubMed ID: 27750448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maternal Respiratory Syncytial Virus Vaccination and Receipt of Respiratory Syncytial Virus Antibody (Nirsevimab) by Infants Aged <8 Months - United States, April 2024.
    Razzaghi H; Garacci E; Kahn KE; Lindley MC; Jones JM; Stokley S; Calhoun K; Black CL
    MMWR Morb Mortal Wkly Rep; 2024 Sep; 73(38):837-843. PubMed ID: 39325675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States.
    Herring WL; Zhang Y; Shinde V; Stoddard J; Talbird SE; Rosen B
    Vaccine; 2022 Jan; 40(3):483-493. PubMed ID: 34933763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.
    Bebia Z; Reyes O; Jeanfreau R; Kantele A; De Leon RG; Sánchez MG; Banooni P; Gardener GJ; Rasero JLB; Pardilla MBE; Langley JM; Di Leo CM; Botelho-Nevers E; Buttery J; Laurichesse H; Madhi SA; García AM; Stanley T; Barjat T; Griffith R; Castrejón-Alba MM; de Heusch M; Dieussaert I; Hercor M; Lese P; Qian H; Tullio AN; Henry O
    J Infect Dis; 2023 Aug; 228(3):299-310. PubMed ID: 36722147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.
    Green CA; Sande CJ; Scarselli E; Capone S; Vitelli A; Nicosia A; Silva-Reyes L; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Hutchings CL; Cargill T; Angus B; Klenerman P; Pollard AJ
    J Infect; 2019 May; 78(5):382-392. PubMed ID: 30742894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults.
    Green CA; Scarselli E; Voysey M; Capone S; Vitelli A; Nicosia A; Cortese R; Thompson AJ; Sande CS; de Lara C; Klenerman P; Pollard AJ
    BMJ Open; 2015 Oct; 5(10):e008748. PubMed ID: 26510727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.
    August A; Glenn GM; Kpamegan E; Hickman SP; Jani D; Lu H; Thomas DN; Wen J; Piedra PA; Fries LF
    Vaccine; 2017 Jun; 35(30):3749-3759. PubMed ID: 28579233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A latent class analysis of factors influencing preferences for infant respiratory syncytial virus (RSV) preventives among pregnant people in the United States.
    Maculaitis MC; Hauber B; Beusterien KM; Will O; Kopenhafer L; Law AW; Vietri JT; Cappelleri JC; Coulter JR; Pugh S; Shea KM
    Hum Vaccin Immunother; 2024 Dec; 20(1):2358566. PubMed ID: 38847198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination against respiratory syncytial virus in pregnancy: a suitable tool to combat global infant morbidity and mortality?
    Saso A; Kampmann B
    Lancet Infect Dis; 2016 Aug; 16(8):e153-63. PubMed ID: 27317449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modelling the household-level impact of a maternal respiratory syncytial virus (RSV) vaccine in a high-income setting.
    Campbell PT; Geard N; Hogan AB
    BMC Med; 2020 Nov; 18(1):319. PubMed ID: 33176774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Challenges in Maximizing Impacts of Preventive Strategies against Respiratory Syncytial Virus (RSV) Disease in Young Children.
    Zheng Z
    Yale J Biol Med; 2022 Jun; 95(2):293-300. PubMed ID: 35782467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study.
    Shoukat A; Bawden CE; Röst G; LeBlanc JJ; Galvani AP; Langley JM; Moghadas SM
    Vaccine; 2024 Mar; 42(7):1768-1776. PubMed ID: 38368226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Passive and active immunization against respiratory syncytial virus for the young and old.
    Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Respiratory Syncytial Virus-Associated Respiratory Diseases in Children and Adults.
    Tenenbaum T; Liese J; Welte T; Rademacher J
    Dtsch Arztebl Int; 2024 May; 121(9):303-312. PubMed ID: 38652840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy.
    Scheltema NM; Kavelaars XM; Thorburn K; Hennus MP; van Woensel JB; van der Ent CK; Borghans JAM; Bont LJ; Drylewicz J
    Vaccine; 2018 Jul; 36(31):4693-4700. PubMed ID: 29941327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Administration of the GSK Respiratory Syncytial Virus Vaccine to Pregnant Persons in Error.
    Moro PL; Gallego R; Scheffey A; Fleming-Dutra KE; Hall E; Zhang B; Marquez P; Jones JM; Nair N; Broder KR
    Obstet Gynecol; 2024 May; 143(5):704-706. PubMed ID: 38394669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Burden of Respiratory Syncytial Virus-Associated Acute Respiratory Infections During Pregnancy.
    Kenmoe S; Chu HY; Dawood FS; Milucky J; Kittikraisak W; Matthewson H; Kulkarni D; Suntarattiwong P; Frivold C; Mohanty S; Havers F; Li Y; Nair H;
    J Infect Dis; 2024 Mar; 229(Supplement_1):S51-S60. PubMed ID: 37824420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimating the burden of respiratory syncytial virus (RSV) on respiratory hospital admissions in children less than five years of age in England, 2007-2012.
    Reeves RM; Hardelid P; Gilbert R; Warburton F; Ellis J; Pebody RG
    Influenza Other Respir Viruses; 2017 Mar; 11(2):122-129. PubMed ID: 28058797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.